Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAdOx1 biEBOV in healthy volunteers
NCT05079750Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ChAdOx1 biEBOV in Ebola virus disease (EVD) and Sudan virus disease (SVD) (3 arms), sponsored by University of Oxford. Primary endpoints: Solicited Local and Systemic Reactogenicity Signs and Symptoms at 7 days, Unsolicited Signs and Symptoms at 28 days and 2 more. Started Nov 2021; status: completed.
02
Drugs
ChAdOx1 biEBOV
03
Conditions
Ebola virus disease (EVD)Sudan virus disease (SVD)
Beyond the preview
Go deeper on NCT05079750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05079750.